Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia | Zendy

Andrew W. Roberts | Zendy; Matthew S. Davids | Zendy; John M. Pagel | Zendy; Brad S. Kahl | Zendy; Soham D. Puvvada | Zendy; John F. Gerecitano | Zendy; Thomas J. Kipps | Zendy; Mary Ann Anderson | Zendy; Jennifer R. Brown | Zendy; Lori A. Gressick | Zendy; Shekman Wong | Zendy; Martin Dunbar | Zendy; Ming Zhu | Zendy; Monali Desai | Zendy; Elisa Cerri | Zendy; Sari H. Enschede | Zendy; Rod Humerickhouse | Zendy; William G. Wierda | Zendy; John F. Seymour | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

Author(s) -

Andrew W. Roberts,

Matthew S. Davids,

John M. Pagel,

Brad S. Kahl,

Soham D. Puvvada,

John F. Gerecitano,

Thomas J. Kipps,

Mary Ann Anderson,

Jennifer R. Brown,

Lori A. Gressick,

Shekman Wong,

Martin Dunbar,

Ming Zhu,

Monali Desai,

Elisa Cerri,

Sari H. Enschede,

Rod Humerickhouse,

William G. Wierda,

John F. Seymour

Publication year - 2015

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1513257

Subject(s) - venetoclax , medicine , fludarabine , chronic lymphocytic leukemia , tumor lysis syndrome , neutropenia , ighv@ , obinutuzumab , cohort , oncology , lymphoma , febrile neutropenia , lymphocytosis , gastroenterology , leukemia , chemotherapy , cyclophosphamide

New treatments have improved outcomes for patients with relapsed chronic lymphocytic leukemia (CLL), but complete remissions remain uncommon. Venetoclax has a distinct mechanism of action; it targets BCL2, a protein central to the survival of CLL cells.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research